Sangamo (SGMO) announced updated data from the Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned gene ...
PROVIDENCE, RI - Ocean Biomedical (NASDAQ: OCEA) has announced research findings that show its immunotherapy candidates can work synergistically with tyrosine kinase inhibitors (TKIs), potentially ...
RICHMOND, Calif. - Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company with a market capitalization of $263 million, has announced promising updated results from its Phase 1/2 STAAR ...
Company Poised to Enter Booming Bispecific Antibody Market Amid Growing Pharma InterestProvidence, RI, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Ocean ...
A year after guidelines were revised to remove the use of race in eGFR, many labs and pathologists were still relying on the ...
The brain of humans and other animals is known to contribute to the protection of the body from infections. Past studies have ...
Our guts are home to trillions of bacteria, and research over the last few decades has established how essential they are to our physiology—in health and disease. A new study from EMBL Heidelberg ...
Hindustan Times on MSN2d
What to do if your body is resisting cancer treatment? Advanced therapies, personalised medicine to address resistanceKnow about the revolutionary therapies, personalised medicine and cancer treatments that are changing the game!
The following is a summary of “Role of glucocorticoid receptor expression in Chronic Chagas Cardiomyopathy: implications for ...
Their findings not only reshape the century-old understanding of the complement system but also open new avenues for therapies that could specifically block this harmful pathway in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback